ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 990

Guanylate Binding Protein 5 (GBP5) Inhibits Rheumatoid Arthritis Synovial Fibroblast Mediated Inflammation and Tissue Destruction

Mahamudul Haque1, Anil K. Singh1 and Salahuddin Ahmed1,2, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 2Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Fibroblasts, Inflammation, interleukins (IL), matrix metalloproteinase (MMP) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Cytokines and Cell Trafficking Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Guanylate binding protein 5 (GBP5), an interferon gamma (IFN-γ) inducible protein, helps to defend against invading pathogens. However, its role and properties beyond anti-viral or anti-bacterial action remains unknown. In the present study, we evaluated the role of GBP5 and its corroboration with IFN-γ in regulating rheumatoid arthritis synovial fibroblast (RASF) mediated inflammation and tissue destruction.

Methods: Cell lysates from RASFs and non-diseased SFs (NLSFs) were prepared to evaluate the expression levels of GBP5 using Western immunoblotting and qRT-PCR methods. siRNA mediated knockdown of GBP5 was conducted to study its effect on IFN-γ (10 ng/ml), IL-1β (10 ng/ml) and/or TNF-α (20 ng/ml)-induced downstream signaling pathway in RASFs. Conditioned media was used to quantitate IL-6, IL-8, matrix metalloproteinase-1 (MMP-1), and CXCL5 production by ELISA. The lentiviral delivery method was used to overexpress GBP5 to evaluate its potential regulatory effects in RASFs.

Results: Our Western blot analysis showed that the expression of GBP5 is significantly reduced in RASFs compared to NLSFs (p<0.05; n=6). We observed a higher expression of GBP5 upon IFN-γ stimulation and the expression was further augmented with IL-1β stimulation (p<0.05; n=6). Co-treatment of RASFs with IFN-γ significantly downregulated IL-1β-induced IL-6, IL-8, and MMP-1 production in RASFs (p<0.05; n=3). To our surprise, siRNA-mediated knockdown of GBP5 reduced the inhibitory potential of IFN-γ and resulted in further upregulation of IL-1β-induced IL-6, IL-8, MMP-1, and CXCL5 production by 84%, 66%, 8-fold, and 72%, respectively (p<0.05; n=3). Evaluating the impact of GBP5 knockdown on the RASF signaling pathways, we observed that GBP5 knockdown in human RASFs selectively amplified the constitutive as well as IL-1β-induced phosphorylation of ERK1/2 and JNK mitogen-activated protein kinases, which are important mediators of inflammation and tissue destruction in RA. Intriguingly, lentivirus-mediated restoration of GBP5 abrogated IL-1β-induced proinflammatory cytokine production, suggesting that GBP5 plays an anti-inflammatory role by inhibiting RASF mediated inflammation.

Conclusion: Our findings suggest that the lack of GBP5 contributes to synovial inflammation, and its restoration suppresses RASF-mediated inflammation and tissue destruction.


Disclosure: M. Haque, None; A. K. Singh, None; S. Ahmed, None.

To cite this abstract in AMA style:

Haque M, Singh AK, Ahmed S. Guanylate Binding Protein 5 (GBP5) Inhibits Rheumatoid Arthritis Synovial Fibroblast Mediated Inflammation and Tissue Destruction [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/guanylate-binding-protein-5-gbp5-inhibits-rheumatoid-arthritis-synovial-fibroblast-mediated-inflammation-and-tissue-destruction/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/guanylate-binding-protein-5-gbp5-inhibits-rheumatoid-arthritis-synovial-fibroblast-mediated-inflammation-and-tissue-destruction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology